DE69233745D1
(de)
|
1991-12-02 |
2008-10-23 |
Cambridge Antibody Tech |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
EP1231268B1
(de)
|
1994-01-31 |
2005-07-27 |
Trustees Of Boston University |
Bibliotheken aus Polyklonalen Antikörpern
|
NZ278607A
(en)
*
|
1994-02-07 |
1999-05-28 |
Knoll Ag |
Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US6165793A
(en)
*
|
1996-03-25 |
2000-12-26 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US20060257890A1
(en)
|
1996-05-20 |
2006-11-16 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6335160B1
(en)
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6309883B1
(en)
|
1994-02-17 |
2001-10-30 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
KR100501838B1
(ko)
*
|
1995-04-24 |
2005-07-21 |
큐비스트 파마슈티컬즈 인코포레이티드 |
새로운 대사 경로를 만들고 이를 스크리닝하는 방법
|
ES2176484T3
(es)
|
1995-08-18 |
2002-12-01 |
Morphosys Ag |
Bancos de proteinas/(poli)peptidos.
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
HU230515B1
(hu)
|
1996-02-09 |
2016-10-28 |
Abbvie Biotechnology Ltd |
Humán TNFalfa-kötő antitestek alkalmazásai
|
AU2013203420B2
(en)
*
|
1996-02-09 |
2014-02-20 |
Abbvie Biotechnology Ltd |
Human antibodies that bind human TNFalpha
|
AU2012261708B2
(en)
*
|
1996-02-09 |
2014-02-20 |
Abbvie Biotechnology Ltd |
Human antibodies that bind human TNFalpha
|
AU2013257402B2
(en)
*
|
1996-02-09 |
2014-02-20 |
Abbvie Biotechnology Ltd |
Human antibodies that bind human TNFalpha
|
AU2006241387B2
(en)
*
|
1996-02-09 |
2009-07-23 |
Abbvie Biotechnology Ltd |
Human antibodies that bind human TNFalpha
|
US6538114B1
(en)
|
1996-04-19 |
2003-03-25 |
Karolina Innovations Ab |
Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
|
US6747136B2
(en)
|
1996-04-19 |
2004-06-08 |
Karolinska Innovations Ab |
Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
|
US5783431A
(en)
*
|
1996-04-24 |
1998-07-21 |
Chromaxome Corporation |
Methods for generating and screening novel metabolic pathways
|
US6242211B1
(en)
|
1996-04-24 |
2001-06-05 |
Terragen Discovery, Inc. |
Methods for generating and screening novel metabolic pathways
|
US6153410A
(en)
*
|
1997-03-25 |
2000-11-28 |
California Institute Of Technology |
Recombination of polynucleotide sequences using random or defined primers
|
AU8755798A
(en)
*
|
1997-04-04 |
1998-11-13 |
Biosite Diagnostics Incorporated |
Polyvalent and polyclonal libraries
|
US20030148463A1
(en)
|
1997-04-14 |
2003-08-07 |
Micromet Ag |
Novel method for the production of anti-human antigen receptors and uses thereof
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
US6610293B1
(en)
*
|
1997-06-16 |
2003-08-26 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
|
GB9712512D0
(en)
|
1997-06-16 |
1997-08-20 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
CA2338865A1
(en)
*
|
1997-07-29 |
1999-02-11 |
James S. Huston |
Methods for detecting binding events using multiple binding partners and muliple targets
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
DE69941453D1
(de)
|
1998-06-12 |
2009-11-05 |
Genentech Inc |
Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
|
US6312689B1
(en)
|
1998-07-23 |
2001-11-06 |
Millennium Pharmaceuticals, Inc. |
Anti-CCR2 antibodies and methods of use therefor
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
IL144600A0
(en)
|
1999-02-12 |
2002-05-23 |
Genetics Inst |
Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
CN1370076A
(zh)
|
1999-08-23 |
2002-09-18 |
中外制药株式会社 |
Hm1.24抗原的表达增强剂
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
US20020086292A1
(en)
|
2000-12-22 |
2002-07-04 |
Shigeaki Harayama |
Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
|
DK1399483T3
(da)
|
2001-01-05 |
2010-08-02 |
Pfizer |
Antistoffer til insulinlignende vækstfaktorrecptor I
|
WO2002064159A1
(en)
|
2001-02-07 |
2002-08-22 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for tumor in hematopoietic organs
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
DK1401498T3
(da)
|
2001-05-30 |
2011-11-21 |
Genentech Inc |
Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
WO2003062370A2
(en)
|
2001-07-19 |
2003-07-31 |
Perlan Therapeutics, Inc. |
Multimeric proteins and methods of making and using same
|
US20060127893A1
(en)
*
|
2001-07-19 |
2006-06-15 |
Stefan Ewert |
Modification of human variable domains
|
EP1427830B1
(de)
|
2001-08-29 |
2012-05-09 |
Genentech, Inc. |
Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
CN100360565C
(zh)
|
2001-12-22 |
2008-01-09 |
4-抗体股份公司 |
制备脊椎动物淋巴细胞和生产结合蛋白的方法
|
US7094579B2
(en)
|
2002-02-13 |
2006-08-22 |
Xoma Technology Ltd. |
Eukaryotic signal sequences for prokaryotic expression
|
US20050118163A1
(en)
|
2002-02-14 |
2005-06-02 |
Hidefumi Mizushima |
Antibody-containing solution pharmaceuticals
|
PT1527100E
(pt)
|
2002-03-29 |
2009-08-25 |
Schering Corp |
Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
EP1513879B1
(de)
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Bibliotheken synthetischer antikörperphagen
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
PT2269656E
(pt)
|
2002-07-15 |
2014-12-02 |
Univ Texas |
Anticorpos selecionados e peptídeos de duramicina que se ligam a fosfolipídios aniônicos e aminofosfolipídios e seus usos no tratamento de infecções virais e câncer
|
EP1541165A4
(de)
|
2002-08-27 |
2009-06-24 |
Chugai Pharmaceutical Co Ltd |
Verfahren zur stabilisierung einer proteinl sungszubereitung
|
EP2261230B1
(de)
|
2002-09-11 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur Proteinreinigung
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US7449616B2
(en)
*
|
2002-12-24 |
2008-11-11 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
CA2516454A1
(en)
|
2003-02-19 |
2004-09-02 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
|
CN104001158A
(zh)
|
2003-03-12 |
2014-08-27 |
健泰科生物技术公司 |
Bv8和/或EG-VEGF促进造血的用途
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
WO2005017155A1
(ja)
|
2003-06-18 |
2005-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーター
|
EP1498133A1
(de)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Verwendung von pak-Inhibitoren zur Behandlung von Gelenkerkrankungen
|
NZ580855A
(en)
*
|
2003-07-21 |
2012-03-30 |
Immunogen Inc |
A CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
US7834155B2
(en)
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
ATE528397T1
(de)
|
2003-08-08 |
2011-10-15 |
Perseus Proteomics Inc |
Bei krebs überexprimiertes gen
|
CN102813923B
(zh)
|
2003-08-27 |
2015-04-01 |
奥普索特克公司 |
用于治疗眼新血管疾病的组合治疗
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
FR2859725B1
(fr)
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
WO2005030039A2
(en)
|
2003-09-23 |
2005-04-07 |
University Of North Carolina At Chapel Hill |
Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
|
US7662929B2
(en)
|
2003-10-10 |
2010-02-16 |
Alchemia Oncology Pty Limited |
Antibody that specifically binds hyaluronan synthase
|
DE602004026897D1
(de)
|
2003-10-14 |
2010-06-10 |
Baxter Healthcare Sa |
Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
|
JP2007521248A
(ja)
|
2003-12-10 |
2007-08-02 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
ヒト化抗ccr2抗体および該抗体を使用する方法
|
ITRM20030601A1
(it)
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
PE20051053A1
(es)
|
2004-01-09 |
2005-12-12 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
ATE452147T1
(de)
|
2004-02-19 |
2010-01-15 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
EP2275445A3
(de)
|
2004-03-12 |
2012-02-29 |
Vasgene Therapeutics, Inc. |
Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
|
RU2429245C2
(ru)
|
2004-03-30 |
2011-09-20 |
Глаксо Груп Лимитед |
Иммуноглобулины
|
EP1740615B1
(de)
|
2004-03-31 |
2014-11-05 |
Genentech, Inc. |
Humanisierte anti-tgf-beta-antikörper
|
JP5301152B2
(ja)
|
2004-04-07 |
2013-09-25 |
ライナット ニューロサイエンス コーポレイション |
神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
|
TWI556829B
(zh)
|
2004-04-09 |
2016-11-11 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
JP2008501638A
(ja)
|
2004-04-23 |
2008-01-24 |
ドイツ連邦共和国 |
ICOS陽性細胞のinvivo枯渇によるT細胞介在病態の治療方法
|
US7311906B2
(en)
|
2004-04-30 |
2007-12-25 |
Brigham Young University |
Anti-viral activity of an anti-thymidine kinase monoclonal antibody
|
CA2810292C
(en)
|
2004-05-14 |
2015-09-29 |
Euroscreen S.A. |
Ligand for g-protein coupled receptor fprl2 and uses thereof
|
US8551486B2
(en)
|
2004-05-21 |
2013-10-08 |
Savoy Pharmaceuticals, Inc. |
Monoclonal antibodies to human thymidine kinase to treat cancer
|
US7837998B2
(en)
|
2004-05-21 |
2010-11-23 |
Nathaniel Lallatin |
Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
BRPI0511755A
(pt)
|
2004-06-01 |
2008-01-02 |
Domantis Ltd |
composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
CN101014365B
(zh)
|
2004-07-16 |
2011-04-13 |
辉瑞产品公司 |
使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
|
US8822644B2
(en)
|
2004-08-02 |
2014-09-02 |
Zenyth Operations Pty Ltd |
Method of treating cancer comprising a VEGF-B antagonist
|
PT2990422T
(pt)
|
2004-09-03 |
2018-10-18 |
Genentech Inc |
Antagonistas humanizados anti-beta7 e suas utilizações
|
EP1841796A2
(de)
|
2004-12-02 |
2007-10-10 |
Domantis Limited |
Bispezifische domänen-antikörper gegen serum albumin und glp-1 oder pyy
|
EP1829961A4
(de)
|
2004-12-22 |
2008-06-04 |
Chugai Pharmaceutical Co Ltd |
Verfahren zur herstellung eines antikörpers unter verwendung einer zelle mit gehemmter fucosetransporterfunktion
|
EP1831258B2
(de)
|
2004-12-28 |
2023-06-07 |
Innate Pharma S.A. |
Monoklonale antikörper gegen nkg2a
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
SI1850873T1
(sl)
|
2005-02-08 |
2019-05-31 |
Genzyme Corporation |
Protitelesa proti TGFBETA
|
EP1861711B1
(de)
|
2005-03-11 |
2012-01-11 |
Sanofi |
Verwendung von mgc4504
|
JP2008532544A
(ja)
|
2005-03-15 |
2008-08-21 |
ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
活性ビタミンk依存性タンパク質を生産するための方法及び組成物
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
EA015534B1
(ru)
|
2005-04-25 |
2011-08-30 |
Пфайзер Инк. |
Антитела к миостатину и способы их применения
|
US20060252096A1
(en)
*
|
2005-04-26 |
2006-11-09 |
Glycofi, Inc. |
Single chain antibody with cleavable linker
|
WO2006114704A2
(en)
|
2005-04-26 |
2006-11-02 |
Pfizer Inc. |
P-cadherin antibodies
|
WO2006119905A1
(en)
|
2005-05-11 |
2006-11-16 |
Sanofi-Aventis |
Use of a gip promoter polymorphism
|
CA2898009C
(en)
|
2005-05-16 |
2018-03-27 |
Rebecca S. Hoffman |
Use of tnfa inhibitor for treatment of erosive polyarthritis
|
MX363423B
(es)
|
2005-05-18 |
2019-03-22 |
Ablynx Nv |
Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
|
CN101213214B
(zh)
|
2005-05-20 |
2014-06-25 |
埃博灵克斯股份有限公司 |
针对冯威勒布兰特因子的单一结构域vhh抗体
|
US8355776B2
(en)
|
2005-05-27 |
2013-01-15 |
Board Of Regents, The University Of Texas System |
Hemoglobin contrast in magneto-motive optical doppler tomography, optical coherence tomography, and ultrasound imaging methods and apparatus
|
US8454511B2
(en)
|
2005-05-27 |
2013-06-04 |
Board Of Regents, The University Of Texas System |
Magneto-motive ultrasound detection of magnetic nanoparticles
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
WO2006138429A2
(en)
|
2005-06-16 |
2006-12-28 |
The Feinstein Institute For Medical Research |
Antibodies against hmgb1 and fragments thereof
|
WO2007094842A2
(en)
|
2005-12-02 |
2007-08-23 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
US7700739B2
(en)
|
2005-06-30 |
2010-04-20 |
Abbott Laboratories |
IL-12/p40 binding proteins
|
US7462698B2
(en)
|
2005-07-22 |
2008-12-09 |
Y's Therapeutics Co., Ltd. |
Anti-CD26 antibodies and methods of use thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
PT2447283E
(pt)
|
2005-09-07 |
2015-10-08 |
Pfizer |
Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1)
|
WO2007039256A2
(de)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
DE102005048898A1
(de)
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
RU2446826C2
(ru)
|
2005-10-14 |
2012-04-10 |
Фукуока Юниверсити |
Агенты для подавления повреждения трансплантированных островков после трансплантации островков
|
CN101330930B
(zh)
|
2005-10-21 |
2011-11-23 |
中外制药株式会社 |
心脏病治疗剂
|
CN103336129A
(zh)
|
2005-11-01 |
2013-10-02 |
阿布维生物技术有限公司 |
使用生物标志物诊断强直性脊柱炎的方法和组合物
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
HUE036940T2
(hu)
|
2005-11-14 |
2018-08-28 |
Teva Pharmaceuticals Int Gmbh |
Kalcitonin gén-rokon peptid ellen irányuló antagonista ellenanyag
|
JP5398987B2
(ja)
|
2005-11-14 |
2014-01-29 |
セルミド リミテッド |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
US20090269335A1
(en)
|
2005-11-25 |
2009-10-29 |
Keio University |
Therapeutic agent for prostate cancer
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
CA2633887C
(en)
|
2005-12-15 |
2015-12-22 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
EP1977763A4
(de)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
Antikörper-enthaltende stabilisierende zubereitung
|
BRPI0706840A2
(pt)
|
2006-01-05 |
2011-04-05 |
Genentech Inc |
anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
|
EP1981910B1
(de)
|
2006-01-13 |
2013-06-26 |
A Chan Holding B.V. |
Verfahren zur identifikation von einem inhibitor der wechselwirkung zwischen glypican und sclerostin
|
CN104189907A
(zh)
|
2006-01-27 |
2014-12-10 |
学校法人庆应义塾 |
伴有脉络膜血管生成的疾病的治疗药
|
JP5406534B2
(ja)
|
2006-03-08 |
2014-02-05 |
アーケミックス エルエルシー |
補体結合アプタマーおよび眼障害の処置において有用な抗c5剤
|
WO2008076139A1
(en)
|
2006-03-10 |
2008-06-26 |
Tethys Bioscience, Inc. |
Multiplex protein fractionation
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP2009101B1
(de)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
KR20090005315A
(ko)
|
2006-04-05 |
2009-01-13 |
애보트 바이오테크놀로지 리미티드 |
항체 정제
|
US9260516B2
(en)
|
2006-04-07 |
2016-02-16 |
Osaka University |
Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
|
US8071323B2
(en)
|
2006-04-07 |
2011-12-06 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Human monoclonal antibodies that bind human insulin like growth factors and their use
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
EP2007426A4
(de)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
EP2666479A3
(de)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
|
US20100080794A1
(en)
|
2006-04-14 |
2010-04-01 |
Takashi Tsuji |
Mutant polypeptide having effector function
|
KR101328756B1
(ko)
|
2006-05-30 |
2013-11-18 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
DK2044120T3
(da)
|
2006-06-07 |
2019-04-15 |
Bioalliance Cv |
Antistoffer, der genkender en kulhydratholdig epitop på cd-43 og cea eksprimeret på cancerceller, og fremgangsmåder til anvendelse deraf
|
JP5043008B2
(ja)
|
2006-06-08 |
2012-10-10 |
中外製薬株式会社 |
炎症性疾患の予防または治療剤
|
CN103316402A
(zh)
|
2006-06-30 |
2013-09-25 |
艾伯维生物技术有限公司 |
自动注射装置
|
KR20090038896A
(ko)
|
2006-07-13 |
2009-04-21 |
추가이 세이야쿠 가부시키가이샤 |
세포사 유도제
|
WO2008010556A1
(fr)
|
2006-07-21 |
2008-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Médicament agissant contre une maladie rénale
|
EP2054444B1
(de)
|
2006-08-04 |
2016-11-02 |
MedImmune Limited |
Antikörper gegen erbb2
|
EP3111955B1
(de)
|
2006-08-14 |
2019-01-23 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnose und behandlung von krebs mittels anti-desmoglein-3 antikörper
|
US9867530B2
(en)
|
2006-08-14 |
2018-01-16 |
Volcano Corporation |
Telescopic side port catheter device with imaging system and method for accessing side branch occlusions
|
ES2817756T3
(es)
|
2006-09-08 |
2021-04-08 |
Abbvie Bahamas Ltd |
Proteínas de unión a interleuquina-13
|
US20100297103A1
(en)
|
2006-09-14 |
2010-11-25 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
NZ576122A
(en)
|
2006-09-26 |
2012-09-28 |
Genmab As |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
CN101594883B
(zh)
|
2006-10-12 |
2018-04-10 |
中外制药株式会社 |
使用抗ereg抗体的癌症的诊断和治疗
|
US8108030B2
(en)
|
2006-10-20 |
2012-01-31 |
Board Of Regents, The University Of Texas System |
Method and apparatus to identify vulnerable plaques with thermal wave imaging of heated nanoparticles
|
CA2666809A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
|
CA2666559A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
RS52452B
(en)
|
2006-10-27 |
2013-02-28 |
Genentech Inc. |
Antibodies and Immunoconjugates and Their Use
|
ATE555128T1
(de)
|
2006-11-30 |
2012-05-15 |
Res Dev Foundation |
Verbesserte immunglobulin-bibliotheken
|
EP2103628A4
(de)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
Monoklonaler anti-claudin-3-antikörper und die behandlung und diagnose von krebs unter dessen verwendung
|
WO2008074839A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
WO2009138519A1
(en)
|
2008-05-16 |
2009-11-19 |
Ablynx Nv |
AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
|
US9156914B2
(en)
|
2006-12-19 |
2015-10-13 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
US20100129358A1
(en)
|
2006-12-22 |
2010-05-27 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
US20100111851A1
(en)
|
2007-01-05 |
2010-05-06 |
The University Of Tokyo |
Diagnosis and treatment of cancer by using anti-prg-3 antibody
|
SG177982A1
(en)
|
2007-01-16 |
2012-02-28 |
Abbott Lab |
Methods for treating psoriasis
|
AU2008208321B2
(en)
|
2007-01-23 |
2013-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Chronic rejection inhibitor
|
CL2008000420A1
(es)
|
2007-02-09 |
2008-06-27 |
Genentech Inc |
Anticuerpo anti-robo4; y su uso para modular la angiogenesis.
|
CA2679266A1
(en)
|
2007-02-27 |
2008-09-04 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
CL2008000935A1
(es)
|
2007-04-02 |
2008-11-07 |
Amgen Fremont Inc |
Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
EP2171451A4
(de)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
Verfahren zur behandlung juveniler idiopathischer arthritis
|
PT2631248T
(pt)
|
2007-06-15 |
2018-02-15 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Tratamento de tumores utilizando um anticorpo anti-l1 específico
|
EP2178442B1
(de)
|
2007-07-12 |
2017-09-06 |
Volcano Corporation |
Katheter für in-vivo-bildgebung
|
US10219780B2
(en)
|
2007-07-12 |
2019-03-05 |
Volcano Corporation |
OCT-IVUS catheter for concurrent luminal imaging
|
US9596993B2
(en)
|
2007-07-12 |
2017-03-21 |
Volcano Corporation |
Automatic calibration systems and methods of use
|
EP2174667B1
(de)
|
2007-07-26 |
2017-01-04 |
Osaka University |
Mittel zur behandlung von augenentzündungen mit interleukin-6-rezeptorhemmer als wirkstoff
|
EP2023144A1
(de)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes
|
JP5759722B2
(ja)
|
2007-08-28 |
2015-08-05 |
アッヴィ バイオテクノロジー リミテッド |
アダリムマブの結合蛋白質を含む組成物及び方法
|
PT2199390T
(pt)
|
2007-08-30 |
2017-03-15 |
Daiichi Sankyo Co Ltd |
Anticorpo anti-epha2
|
EP4339294A2
(de)
|
2007-09-26 |
2024-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers durch aminosäuresubstitution in cdr
|
MX2010003158A
(es)
|
2007-09-28 |
2010-04-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-glipicano-3 que tiene cinetica mejorada en plasma.
|
RU2490025C2
(ru)
|
2007-10-02 |
2013-08-20 |
Чугаи Сейяку Кабусики Кайся |
Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
|
US8470560B2
(en)
|
2007-10-03 |
2013-06-25 |
The United States Of America As Represented By The Secretary Of The Army |
CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
|
HUE025262T2
(en)
|
2007-10-11 |
2016-02-29 |
Daiichi Sankyo Co Ltd |
Antibody targeting osteoclast-linked Siglec-15 protein
|
KR101558009B1
(ko)
|
2007-10-15 |
2015-10-19 |
추가이 세이야쿠 가부시키가이샤 |
항체의 제조 방법
|
EP2230300A4
(de)
|
2007-10-24 |
2012-08-08 |
Otsuka Chemical Holdings Co Ltd |
Polypeptid mit verbesserter effektorfunktion
|
US8663980B2
(en)
|
2007-10-26 |
2014-03-04 |
Janssen Biotech, Inc. |
Vectors, host cells, and methods of production and uses
|
RS57021B1
(sr)
|
2007-11-07 |
2018-05-31 |
Genentech Inc |
Il-22 za upotrebu u tretiranju mikrobnih poremećaja
|
WO2009063970A1
(ja)
|
2007-11-14 |
2009-05-22 |
Forerunner Pharma Research Co., Ltd. |
抗gpr49抗体を用いる癌の診断および治療
|
TW200936160A
(en)
|
2007-11-15 |
2009-09-01 |
Chugai Pharmaceutical Co Ltd |
Monoclonal antibodies that bind to anexelekto and uses thereof
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
EP2808345A3
(de)
|
2007-12-05 |
2015-03-11 |
Massachusetts Institute of Technology |
Aglycosylierte Immunoglobulinmutanten
|
JP5475460B2
(ja)
|
2007-12-05 |
2014-04-16 |
中外製薬株式会社 |
掻痒症治療剤
|
AU2008332271C1
(en)
|
2007-12-05 |
2014-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-NR10 antibody and use thereof
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
SI2594590T1
(sl)
|
2007-12-14 |
2015-03-31 |
Bristol-Myers Squibb Company |
Postopek za izdelavo vezavnih molekul za humani receptor OX40
|
CA2706502C
(en)
|
2007-12-18 |
2018-08-07 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
EP3181588A1
(de)
|
2008-01-11 |
2017-06-21 |
Adheron Therapeutics, Inc. |
Cadherin-11 antagonisten und verfahren zur behandlung entzündlichen gelenkerkrankungen
|
CA2711557A1
(en)
|
2008-01-11 |
2009-07-16 |
The University Of Tokyo |
Anti-cldn6 antibody
|
RU2537139C2
(ru)
|
2008-01-15 |
2014-12-27 |
Эбботт Гмбх Унд Ко.Кг |
Порошковые белковые композиции и способы их получения
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2098536A1
(de)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
|
AU2009225797A1
(en)
|
2008-03-18 |
2009-09-24 |
Abbvie Inc. |
Methods for treating psoriasis
|
EP2105742A1
(de)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Verwendung von Kathepsin-C
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
EP2947097A1
(de)
|
2008-04-07 |
2015-11-25 |
Ablynx N.V. |
Gegen Notch-Signalwege gerichtete Aminosäuresequenzen und Verwendungen davon
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
MY159667A
(en)
|
2008-05-09 |
2017-01-13 |
Abbvie Inc |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
BRPI0913406A2
(pt)
|
2008-06-03 |
2018-01-09 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e usos das mesmas
|
TWI528973B
(zh)
|
2008-06-05 |
2016-04-11 |
Chugai Pharmaceutical Co Ltd |
Nerve infiltration inhibitor
|
US8741287B2
(en)
|
2008-06-18 |
2014-06-03 |
Abbott Laboratories |
PlGF-1 assay and kits and components thereof
|
CN102124030B
(zh)
|
2008-06-20 |
2015-06-17 |
国立大学法人冈山大学 |
抗氧化LDL/β2GPI复合物的抗体及其用途
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
MY153074A
(en)
|
2008-08-14 |
2014-12-31 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-il-12/11-23 antibodies
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
PE20150682A1
(es)
|
2008-10-14 |
2015-05-20 |
Genentech Inc |
Variantes de inmunoglobulinas y sus usos
|
ES2732504T3
(es)
|
2008-10-29 |
2019-11-22 |
Circular Commitment Company |
Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
|
US8497075B2
(en)
|
2008-12-09 |
2013-07-30 |
Novartis Ag |
Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands
|
TW201029662A
(en)
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
US8349325B2
(en)
|
2008-12-23 |
2013-01-08 |
Abbott Laboratories |
Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
|
US20120009182A1
(en)
|
2008-12-23 |
2012-01-12 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
CA2748990A1
(en)
|
2008-12-26 |
2010-07-01 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-lgr7 antibody
|
WO2010081890A1
(en)
|
2009-01-19 |
2010-07-22 |
Innate Pharma |
Anti-kir3d antibodies
|
RU2011135768A
(ru)
|
2009-01-29 |
2013-03-10 |
Эбботт Лэборетриз |
Белки, связывающие il-1
|
EP2219029A1
(de)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Testsysteme, Verfahren und Verwendungen, die AS160-Protein einbeziehen
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
WO2010099536A2
(en)
|
2009-02-27 |
2010-09-02 |
Massachusetts Institute Of Technology |
Engineered proteins with high affinity for dota chelates
|
NZ611324A
(en)
|
2009-03-05 |
2015-02-27 |
Abbvie Inc |
Il-17 binding proteins
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
TWI507205B
(zh)
|
2009-03-25 |
2015-11-11 |
Genentech Inc |
抗fgfr3抗體及使用方法
|
US8575316B2
(en)
|
2009-04-09 |
2013-11-05 |
Daiichi Sankyo Company, Limited |
Anti-Siglec-15 antibody
|
WO2010115998A2
(en)
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
TWI583418B
(zh)
|
2009-04-29 |
2017-05-21 |
艾伯維生物技術有限責任公司 |
針筒柱塞及自動注射裝置
|
JP5723270B2
(ja)
|
2009-05-01 |
2015-05-27 |
国立大学法人 東京大学 |
抗カドヘリン抗体
|
EP2270053A1
(de)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanisierte AXL-Antikörper
|
JP5797642B2
(ja)
|
2009-05-20 |
2015-10-21 |
ノビミューン エスアー |
合成ポリペプチドライブラリーおよび天然で多様化されたポリペプチドバリアントを作製するための方法
|
NZ596603A
(en)
|
2009-05-29 |
2013-07-26 |
Morphosys Ag |
A collection of antibodies or fragments having properties relevant to developability
|
US20120141501A1
(en)
|
2009-05-29 |
2012-06-07 |
Forerunner Pharma Research Co. Ltd |
Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
|
CN102459332B
(zh)
|
2009-06-05 |
2015-08-19 |
埃博灵克斯股份有限公司 |
用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
|
RU2011151287A
(ru)
|
2009-06-18 |
2013-07-27 |
Пфайзер Инк. |
АНТИ Notch-1 АНТИТЕЛА
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
US20120183539A1
(en)
|
2009-07-31 |
2012-07-19 |
Shin Maeda |
Cancer Metastasis Inhibitor
|
WO2011021381A1
(ja)
|
2009-08-17 |
2011-02-24 |
株式会社未来創薬研究所 |
抗hb-egf抗体を有効成分として含む医薬組成物
|
KR101588598B1
(ko)
|
2009-08-17 |
2016-01-29 |
로슈 글리카트 아게 |
표적화된 면역접합체
|
AU2010286518C1
(en)
|
2009-08-29 |
2015-08-27 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
EP2293072A1
(de)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Verwendung von Kathepsin H
|
RU2012112550A
(ru)
|
2009-09-01 |
2013-10-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
RU2012114854A
(ru)
|
2009-09-14 |
2013-10-27 |
Эбботт Лэборетриз |
Способы лечения псориаза
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
CN103403026B
(zh)
|
2009-09-25 |
2016-05-11 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1中和抗体及其用途
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
ES2534646T3
(es)
|
2009-10-22 |
2015-04-27 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-hepsina y métodos de uso de los mismos
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
EP2496601B1
(de)
|
2009-11-05 |
2017-06-07 |
F. Hoffmann-La Roche AG |
Methoden und zusammensetzung zur sekretion heterologer polypeptide
|
MX2012005464A
(es)
|
2009-11-12 |
2012-06-08 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas.
|
US9872905B2
(en)
|
2009-12-01 |
2018-01-23 |
President And Fellows Of Harvard College |
Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
AU2010329955A1
(en)
|
2009-12-08 |
2012-05-24 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
|
JP5818805B2
(ja)
|
2009-12-11 |
2015-11-18 |
ジェネンテック, インコーポレイテッド |
抗vegf−c抗体及びその使用方法
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
ES2765657T3
(es)
|
2009-12-21 |
2020-06-10 |
Hoffmann La Roche |
Formulación farmacéutica de bevacizumab
|
CN103068849B
(zh)
|
2009-12-23 |
2016-04-06 |
霍夫曼-拉罗奇有限公司 |
抗Bv8抗体及其用途
|
WO2011082345A2
(en)
|
2009-12-30 |
2011-07-07 |
Brigham Young University |
Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
AR080027A1
(es)
|
2010-01-28 |
2012-03-07 |
Glaxo Group Ltd |
Proteinas de union a cd127
|
WO2011092989A1
(ja)
|
2010-01-29 |
2011-08-04 |
東レ株式会社 |
ポリ乳酸系樹脂シート
|
CN102959088A
(zh)
|
2010-02-02 |
2013-03-06 |
艾博特生物技术有限公司 |
用于预测对TNF-α抑制剂治疗的反应性的方法和组合物
|
US8815211B2
(en)
|
2010-02-10 |
2014-08-26 |
Fujifilm Ri Pharma Co., Ltd. |
Radioactive metal-labeled anti-cadherin antibody
|
DK2538976T3
(en)
|
2010-02-24 |
2017-02-27 |
Immunogen Inc |
IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF
|
TWI596114B
(zh)
|
2010-02-24 |
2017-08-21 |
雷那特神經科學股份有限公司 |
拮抗劑抗-il-7受體抗體及方法
|
EP3072904A1
(de)
|
2010-03-02 |
2016-09-28 |
Abbvie Inc. |
Therapeutische dll4-bindende proteine
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
EP2543730B1
(de)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Variante einer konstanten antikörperregion
|
EP2545079A2
(de)
|
2010-03-11 |
2013-01-16 |
Rinat Neuroscience Corporation |
Antikörper mit ph-abhängiger antigenbindung
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
DK2560672T3
(en)
|
2010-04-19 |
2014-03-17 |
Res Dev Foundation |
RTEF-1 variants and their uses
|
CA2835489C
(en)
|
2010-05-10 |
2018-03-06 |
Chi-Huey Wong |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
PE20130205A1
(es)
|
2010-05-14 |
2013-03-24 |
Abbvie Inc |
Proteinas de union a il-1
|
WO2011149046A1
(ja)
|
2010-05-28 |
2011-12-01 |
独立行政法人国立がん研究センター |
膵癌治療剤
|
PL2578231T3
(pl)
|
2010-05-28 |
2023-01-16 |
Chugai Seiyaku Kabushiki Kaisha |
Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
|
JP6048973B2
(ja)
|
2010-06-03 |
2016-12-27 |
ジェネンテック, インコーポレイテッド |
抗体及びイムノコンジュゲートのイムノpetイメージング及びこれらの使用方法
|
CA2801917C
(en)
|
2010-06-03 |
2017-04-25 |
Abbvie Biotechnology Ltd |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
US9499813B2
(en)
|
2010-06-10 |
2016-11-22 |
President And Fellows Of Harvard College |
Systems and methods for amplification and phage display
|
RU2615684C2
(ru)
|
2010-06-14 |
2017-04-06 |
Ликера Биомед Са |
Специфическое антитело к s100a4 или его фрагмент (варианты), способ их получения (варианты), фармацевтическая композиция, их содержащая, гибридомная клеточная линия (варианты), конъюгат, композиция, способ предупреждения и/или лечения рака, метастазирования, ангиогенеза и воспалительных заболеваний, способ и набор для диагностики рака или заболевания, ассоциированного с воспалением, (варианты), способ детекции s100a4, способ создания индивидуальной терапии
|
NO2593128T3
(de)
|
2010-07-15 |
2018-06-09 |
|
|
JP2013537415A
(ja)
|
2010-08-03 |
2013-10-03 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
PT3333188T
(pt)
|
2010-08-19 |
2022-03-28 |
Zoetis Belgium S A |
Anticorpos de anti-ngf e a sua utilização
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
AU2011301803A1
(en)
|
2010-09-17 |
2013-03-21 |
Baxalta GmbH |
Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
WO2012061120A1
(en)
|
2010-10-25 |
2012-05-10 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
SG10202100921YA
(en)
|
2010-10-27 |
2021-03-30 |
Univ New York State Res Found |
Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
|
US9328160B2
(en)
|
2010-10-29 |
2016-05-03 |
Perseus Proteomics Inc. |
Anti-CDH3 antibody having high internalization capacity
|
CA2816291C
(en)
|
2010-10-29 |
2016-08-23 |
Daiichi Sankyo Company, Limited |
Anti-dr5 antibody
|
US20120115244A1
(en)
|
2010-11-09 |
2012-05-10 |
Abbott Laboratories |
Materials and methods for immunoassay of pterins
|
US9072766B2
(en)
|
2010-11-18 |
2015-07-07 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
|
NZ609707A
(en)
|
2010-11-19 |
2014-12-24 |
Morphosys Ag |
A collection and methods for its use
|
UA114077C2
(xx)
|
2010-11-19 |
2017-04-25 |
|
Нейтралізуюче антитіло проти ccl20
|
EP4279512A3
(de)
|
2010-11-30 |
2024-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Zytotoxizitätsinduzierendes therapeutikum
|
CA2819356C
(en)
|
2010-11-30 |
2023-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
RU2622083C2
(ru)
|
2010-12-15 |
2017-06-09 |
ВАЙЕТ ЭлЭлСи |
Антитела против notch1
|
TW201238973A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
US9631002B2
(en)
|
2010-12-21 |
2017-04-25 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin K-dependent proteins
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
US11141063B2
(en)
|
2010-12-23 |
2021-10-12 |
Philips Image Guided Therapy Corporation |
Integrated system architectures and methods of use
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US11040140B2
(en)
|
2010-12-31 |
2021-06-22 |
Philips Image Guided Therapy Corporation |
Deep vein thrombosis therapeutic methods
|
RU2727040C2
(ru)
|
2011-01-24 |
2020-07-17 |
Эббви Байотекнолоджи Лтд. |
Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
US8952132B2
(en)
|
2011-02-07 |
2015-02-10 |
Research Development Foundation |
Engineered immunoglobulin FC polypeptides
|
BR112013021526B1
(pt)
|
2011-02-25 |
2021-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
|
US9987356B2
(en)
|
2011-03-11 |
2018-06-05 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-CD40 antibodies and methods of administering thereof
|
AU2012233313C1
(en)
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
WO2012138774A2
(en)
|
2011-04-04 |
2012-10-11 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
EP2700652B1
(de)
|
2011-04-18 |
2018-12-19 |
The University of Tokyo |
Diagnose und behandlung von krebs mittels anti-itm2a-antikörpern
|
RS57279B1
(sr)
|
2011-04-25 |
2018-08-31 |
Daiichi Sankyo Co Ltd |
Anti-b7-h3 antitelo
|
EP2518157A1
(de)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Testsysteme und Verfahren zur Identifizierung einer Verbindung, die die zelluläre DDR-Aktivität verändert
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EP2708560A4
(de)
|
2011-05-09 |
2015-01-14 |
Perseus Proteomics Inc |
Antikörper zum spezifischen nachweis von transferrin-rezeptoren
|
BR112013030298A2
(pt)
|
2011-05-27 |
2017-12-12 |
Ablynx Nv |
inibição da reabsorção óssea com peptídeos que se ligam ao rankl
|
EP2537532A1
(de)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
|
EP2728002B1
(de)
|
2011-06-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerisiertes polypeptid
|
JP6176849B2
(ja)
|
2011-07-19 |
2017-08-09 |
中外製薬株式会社 |
アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
|
WO2013027802A1
(ja)
|
2011-08-23 |
2013-02-28 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
WO2013033489A1
(en)
|
2011-08-31 |
2013-03-07 |
Volcano Corporation |
Optical rotary joint and methods of use
|
JP6077997B2
(ja)
|
2011-09-07 |
2017-02-08 |
中外製薬株式会社 |
癌幹細胞の分離
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
CN108144058A
(zh)
|
2011-09-30 |
2018-06-12 |
中外制药株式会社 |
促进抗原消除的抗原结合分子
|
CN110655578A
(zh)
|
2011-09-30 |
2020-01-07 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
KR102276528B1
(ko)
|
2011-09-30 |
2021-07-12 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존성 결합 분자 라이브러리
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
WO2013051294A1
(ja)
|
2011-10-05 |
2013-04-11 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
PL2766393T3
(pl)
|
2011-10-14 |
2018-11-30 |
F.Hoffmann-La Roche Ag |
PRZECIWCIAŁA PRZECIW HtrA1 I SPOSOBY ZASTOSOWANIA
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
WO2013062083A1
(ja)
|
2011-10-28 |
2013-05-02 |
ファーマロジカルズ・リサーチ プライベート リミテッド |
癌幹細胞特異的分子
|
ES2732712T3
(es)
|
2011-10-31 |
2019-11-25 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
|
BR112014011115A2
(pt)
|
2011-11-08 |
2017-06-13 |
Pfizer |
métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
|
TWI495644B
(zh)
|
2011-11-11 |
2015-08-11 |
Rinat Neuroscience Corp |
營養層細胞表面抗原(Trop-2)之專一性抗體類及彼等之用途
|
KR20140125351A
(ko)
|
2011-11-23 |
2014-10-28 |
이제니카 바이오테라퓨틱스, 인크. |
항-cd98 항체 및 이의 사용 방법
|
US20140017174A1
(en)
|
2011-11-30 |
2014-01-16 |
Raja Atreya |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
|
WO2013093707A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
CN104159920A
(zh)
|
2011-12-30 |
2014-11-19 |
艾伯维公司 |
针对il-13和/或il-17的双重可变结构域免疫球蛋白
|
DK2807192T3
(en)
|
2012-01-27 |
2018-07-23 |
Abbvie Deutschland |
COMPOSITION AND PROCEDURE FOR DIAGNOSTICATION AND TREATMENT OF DISEASES RELATED TO NEURITE DEGENERATION
|
EP2813568A4
(de)
|
2012-02-09 |
2016-04-06 |
Chugai Pharmaceutical Co Ltd |
Modifizierte fc-antikörperregionen
|
TW202231872A
(zh)
|
2012-02-24 |
2022-08-16 |
日商中外製藥股份有限公司 |
經FcγRIIB促進抗原消失之抗原結合分子
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
US20150125470A1
(en)
|
2012-03-30 |
2015-05-07 |
Daiichi Sankyo Company, Limited |
Novel anti-siglec-15 antibody
|
AU2012376421A1
(en)
|
2012-04-04 |
2014-11-13 |
Perseus Proteomics Inc. |
Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
|
EP2837685B1
(de)
|
2012-04-09 |
2020-09-09 |
Daiichi Sankyo Company, Limited |
Anti-fgfr2-antikörper
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9505833B2
(en)
|
2012-04-20 |
2016-11-29 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
KR101950898B1
(ko)
|
2012-04-27 |
2019-02-22 |
다이이찌 산쿄 가부시키가이샤 |
항-robo4 항체
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
BR112014029274B1
(pt)
|
2012-05-24 |
2022-02-15 |
Mountgate Innotech (Hk) Limited |
Anticorpo isolado, composição farmacêutica, uso do anticorpo, e, kit para tratar infecção rábica
|
TWI617578B
(zh)
|
2012-05-30 |
2018-03-11 |
Chugai Pharmaceutical Co Ltd |
標的組織專一的抗原結合分子
|
US20150353630A1
(en)
|
2012-05-30 |
2015-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
EP2859018B1
(de)
|
2012-06-06 |
2021-09-22 |
Zoetis Services LLC |
Anti-ngf-antikörper für hunde und verfahren dafür
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
PE20150646A1
(es)
|
2012-08-16 |
2015-05-21 |
Ipierian Inc |
Metodos de tratamiento de una tauopatia
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
ES2776681T3
(es)
|
2012-08-24 |
2020-07-31 |
Chugai Pharmaceutical Co Ltd |
Variante de la región Fc específica de FcgammaRIIb
|
US11236168B2
(en)
|
2012-08-24 |
2022-02-01 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse FcγammaRII-specific Fc antibody
|
RS60217B1
(sr)
|
2012-08-31 |
2020-06-30 |
Immunogen Inc |
Dijagnostički testovi i kompleti za detekciju folatnog receptora 1
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
TWI606066B
(zh)
|
2012-09-27 |
2017-11-21 |
中外製藥股份有限公司 |
FGFR3 Fusion Gene and Its Targeted Medicine
|
JP6280040B2
(ja)
*
|
2012-10-03 |
2018-02-14 |
株式会社カイオム・バイオサイエンス |
invivoで抗腫瘍活性を有する抗ヒトDlk−1抗体
|
US9292918B2
(en)
|
2012-10-05 |
2016-03-22 |
Volcano Corporation |
Methods and systems for transforming luminal images
|
US11272845B2
(en)
|
2012-10-05 |
2022-03-15 |
Philips Image Guided Therapy Corporation |
System and method for instant and automatic border detection
|
US9286673B2
(en)
|
2012-10-05 |
2016-03-15 |
Volcano Corporation |
Systems for correcting distortions in a medical image and methods of use thereof
|
US9324141B2
(en)
|
2012-10-05 |
2016-04-26 |
Volcano Corporation |
Removal of A-scan streaking artifact
|
US10568586B2
(en)
|
2012-10-05 |
2020-02-25 |
Volcano Corporation |
Systems for indicating parameters in an imaging data set and methods of use
|
US9307926B2
(en)
|
2012-10-05 |
2016-04-12 |
Volcano Corporation |
Automatic stent detection
|
US9858668B2
(en)
|
2012-10-05 |
2018-01-02 |
Volcano Corporation |
Guidewire artifact removal in images
|
US9367965B2
(en)
|
2012-10-05 |
2016-06-14 |
Volcano Corporation |
Systems and methods for generating images of tissue
|
US10070827B2
(en)
|
2012-10-05 |
2018-09-11 |
Volcano Corporation |
Automatic image playback
|
JP2015532536A
(ja)
|
2012-10-05 |
2015-11-09 |
デイビッド ウェルフォード, |
光を増幅するためのシステムおよび方法
|
CA2886120A1
(en)
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
SG11201502757QA
(en)
|
2012-10-09 |
2015-05-28 |
Igenica Biotherapeutics Inc |
Anti-c16orf54 antibodies and methods of use thereof
|
KR102417310B1
(ko)
|
2012-10-11 |
2022-07-05 |
다이이찌 산쿄 가부시키가이샤 |
글리신아미드 화합물의 제조 방법
|
US9872924B2
(en)
|
2012-10-19 |
2018-01-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
US9840734B2
(en)
|
2012-10-22 |
2017-12-12 |
Raindance Technologies, Inc. |
Methods for analyzing DNA
|
AU2013334229B2
(en)
|
2012-10-25 |
2018-02-15 |
Bioverativ Usa Inc. |
Anti-complement C1s antibodies and uses thereof
|
JP6109952B2
(ja)
|
2012-11-01 |
2017-04-05 |
アッヴィ・インコーポレイテッド |
抗vegf/dll4二重可変ドメイン免疫グロブリンおよびこれらの使用
|
CN104884088B
(zh)
|
2012-11-02 |
2018-06-15 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
CN110669136A
(zh)
|
2012-11-05 |
2020-01-10 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
PL2918603T3
(pl)
|
2012-11-08 |
2019-01-31 |
University Of Miyazaki |
Przeciwciało zdolne do specyficznego rozpoznawania receptora transferyny
|
RU2670943C9
(ru)
|
2012-11-08 |
2018-11-26 |
Илэвэн Байотерапьютикс, Инк. |
Антагонисты ил-6 и их применение
|
JP2015536339A
(ja)
|
2012-11-09 |
2015-12-21 |
ファイザー・インク |
血小板由来増殖因子b特異的抗体ならびにこれらの組成物および使用
|
US10407503B2
(en)
|
2012-11-30 |
2019-09-10 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-Met
|
EP2931132B1
(de)
|
2012-12-13 |
2023-07-05 |
Philips Image Guided Therapy Corporation |
Vorrichtung zur gezielten kanülierung
|
EP2934310A4
(de)
|
2012-12-20 |
2016-10-12 |
Nathaniel J Kemp |
Optisches kohärenztomografiesystem zwischen verschiedenen rekonfigurierbaren bildgebungsmodi
|
WO2014100602A1
(en)
|
2012-12-20 |
2014-06-26 |
Hospital For Special Surgery |
Treatment of egf-receptor dependent pathologies
|
US10942022B2
(en)
|
2012-12-20 |
2021-03-09 |
Philips Image Guided Therapy Corporation |
Manual calibration of imaging system
|
US11406498B2
(en)
|
2012-12-20 |
2022-08-09 |
Philips Image Guided Therapy Corporation |
Implant delivery system and implants
|
US10939826B2
(en)
|
2012-12-20 |
2021-03-09 |
Philips Image Guided Therapy Corporation |
Aspirating and removing biological material
|
US10595820B2
(en)
|
2012-12-20 |
2020-03-24 |
Philips Image Guided Therapy Corporation |
Smooth transition catheters
|
CA2895770A1
(en)
|
2012-12-20 |
2014-07-24 |
Jeremy Stigall |
Locating intravascular images
|
JP2016507892A
(ja)
|
2012-12-21 |
2016-03-10 |
デイビッド ウェルフォード, |
光の波長放出を狭幅化するためのシステムおよび方法
|
US10058284B2
(en)
|
2012-12-21 |
2018-08-28 |
Volcano Corporation |
Simultaneous imaging, monitoring, and therapy
|
US9612105B2
(en)
|
2012-12-21 |
2017-04-04 |
Volcano Corporation |
Polarization sensitive optical coherence tomography system
|
CA2895769A1
(en)
|
2012-12-21 |
2014-06-26 |
Douglas Meyer |
Rotational ultrasound imaging catheter with extended catheter body telescope
|
WO2014099760A1
(en)
|
2012-12-21 |
2014-06-26 |
Mai Jerome |
Ultrasound imaging with variable line density
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
WO2014100530A1
(en)
|
2012-12-21 |
2014-06-26 |
Whiseant Chester |
System and method for catheter steering and operation
|
CA2895993A1
(en)
|
2012-12-21 |
2014-06-26 |
Jason Spencer |
System and method for graphical processing of medical data
|
US10420530B2
(en)
|
2012-12-21 |
2019-09-24 |
Volcano Corporation |
System and method for multipath processing of image signals
|
US9486143B2
(en)
|
2012-12-21 |
2016-11-08 |
Volcano Corporation |
Intravascular forward imaging device
|
JP2016508233A
(ja)
|
2012-12-21 |
2016-03-17 |
ナサニエル ジェイ. ケンプ, |
光学スイッチを用いた電力効率のよい光学バッファリング
|
KR102249779B1
(ko)
|
2012-12-27 |
2021-05-07 |
추가이 세이야쿠 가부시키가이샤 |
헤테로이량화 폴리펩티드
|
US10226597B2
(en)
|
2013-03-07 |
2019-03-12 |
Volcano Corporation |
Guidewire with centering mechanism
|
EP2965263B1
(de)
|
2013-03-07 |
2022-07-20 |
Bernhard Sturm |
Multimodale segmentierung in intravaskulären bildern
|
JP6371758B2
(ja)
|
2013-03-12 |
2018-08-08 |
全薬工業株式会社 |
抗ブドウ球菌抗体、その製造方法並びにその使用
|
CN105228518B
(zh)
|
2013-03-12 |
2018-10-09 |
火山公司 |
用于诊断冠状微脉管疾病的***和方法
|
US20140276923A1
(en)
|
2013-03-12 |
2014-09-18 |
Volcano Corporation |
Vibrating catheter and methods of use
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
NZ711567A
(en)
|
2013-03-13 |
2020-04-24 |
Genentech Inc |
Antibody formulations
|
BR112015022475A8
(pt)
|
2013-03-13 |
2019-11-26 |
Genentech Inc |
formulação líquida e método para impedir a oxidação de uma proteína em uma formulação de proteína
|
JP6339170B2
(ja)
|
2013-03-13 |
2018-06-06 |
ジンヒョン パーク |
回転式血管内超音波装置から画像を生成するためのシステム及び方法
|
US9301687B2
(en)
|
2013-03-13 |
2016-04-05 |
Volcano Corporation |
System and method for OCT depth calibration
|
US11026591B2
(en)
|
2013-03-13 |
2021-06-08 |
Philips Image Guided Therapy Corporation |
Intravascular pressure sensor calibration
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
SG10201705525VA
(en)
|
2013-03-13 |
2017-08-30 |
Genentech Inc |
Formulations with reduced oxidation
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
US10093921B2
(en)
|
2013-03-14 |
2018-10-09 |
The Governing Council Of The University Of Toronto |
Scaffolded peptidic libraries and methods of making and screening the same
|
US10219887B2
(en)
|
2013-03-14 |
2019-03-05 |
Volcano Corporation |
Filters with echogenic characteristics
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
EP2968550B1
(de)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Zusammensetzungen und verfahren zur behandlung von angiogenesebedingten erkrankungen
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
US10292677B2
(en)
|
2013-03-14 |
2019-05-21 |
Volcano Corporation |
Endoluminal filter having enhanced echogenic properties
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
WO2014152365A2
(en)
|
2013-03-14 |
2014-09-25 |
Volcano Corporation |
Filters with echogenic characteristics
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
RU2718986C2
(ru)
|
2013-03-15 |
2020-04-15 |
Дженентек, Инк. |
Композиции клеточных культур с антиоксидантами и способы получения полипептидов
|
US9688747B2
(en)
|
2013-03-15 |
2017-06-27 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the generation and use of conformation-specific antibodies
|
CN105246510A
(zh)
|
2013-03-15 |
2016-01-13 |
豪夫迈·罗氏有限公司 |
细胞培养培养基和抗体生产方法
|
EP3783017A1
(de)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Varianten der fc-region
|
US10501802B2
(en)
|
2013-04-30 |
2019-12-10 |
Universite De Montreal |
Biomarkers for acute myeloid leukemia
|
AU2014264295A1
(en)
|
2013-05-07 |
2015-10-29 |
Rinat Neuroscience Corp. |
Anti-glucagon receptor antibodies and methods of use thereof
|
CN107095872A
(zh)
|
2013-05-16 |
2017-08-29 |
国立大学法人京都大学 |
用于确定癌症预后的方法
|
CN105339002B
(zh)
|
2013-06-10 |
2019-06-28 |
伊皮埃里安股份有限公司 |
治疗tau病变的方法
|
JP6442404B2
(ja)
|
2013-06-11 |
2018-12-19 |
国立研究開発法人国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
WO2014208482A1
(ja)
|
2013-06-24 |
2014-12-31 |
中外製薬株式会社 |
ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
KR101809072B1
(ko)
|
2013-08-02 |
2017-12-14 |
화이자 인코포레이티드 |
항-cxcr4 항체 및 항체-약물 접합체
|
WO2015034052A1
(ja)
|
2013-09-05 |
2015-03-12 |
国立大学法人 宮崎大学 |
ヒトインテグリンa6b4と特異的に反応する抗体
|
WO2015035337A1
(en)
|
2013-09-06 |
2015-03-12 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
|
US20160229922A1
(en)
|
2013-09-20 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
EP3049438B1
(de)
|
2013-09-24 |
2018-07-25 |
The Feinstein Institute for Medical Research |
Peptide zur hemmung von kälteinduzierbarer rns-bindender proteinaktivität
|
ES2894333T3
(es)
|
2013-09-26 |
2022-02-14 |
Beth Israel Deaconess Medical Ct Inc |
Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo
|
CA2925310C
(en)
|
2013-09-27 |
2022-12-06 |
Genentech, Inc. |
Anti-pdl1 antibody formulations
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
CA2925897A1
(en)
|
2013-09-30 |
2015-04-02 |
Daiichi Sankyo Company, Limited |
Anti-lps o11 antibody
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
ES2768618T3
(es)
|
2013-10-08 |
2020-06-23 |
Daiichi Sankyo Co Ltd |
Combinación de anticuerpo anti-FGFR2 y otro agente
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
EP3069137A1
(de)
|
2013-11-05 |
2016-09-21 |
Novartis Ag |
Organische verbindungen
|
CN105940107B
(zh)
|
2013-11-11 |
2021-06-15 |
中外制药株式会社 |
含有改变了抗体可变区的抗原结合分子
|
BR112016009797A2
(pt)
|
2013-11-13 |
2017-12-05 |
Bristol Myers Squibb Co |
anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
EA038994B1
(ru)
|
2013-11-27 |
2021-11-18 |
Айпириэн, Инк. |
Способы лечения таупатии
|
NZ720311A
(en)
|
2013-12-02 |
2022-10-28 |
Baylor College Medicine |
Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
|
TWI702316B
(zh)
|
2013-12-04 |
2020-08-21 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
KR20230107382A
(ko)
|
2013-12-09 |
2023-07-14 |
알라코스 인크. |
항-Siglec-8 항체 및 그의 사용 방법
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
KR102088169B1
(ko)
|
2013-12-25 |
2020-03-12 |
다이이찌 산쿄 가부시키가이샤 |
항 trop2 항체-약물 컨쥬게이트
|
AU2014370873B2
(en)
|
2013-12-27 |
2020-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying antibody having low isoelectric point
|
WO2015099127A1
(ja)
|
2013-12-27 |
2015-07-02 |
中外製薬株式会社 |
Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
MY191944A
(en)
|
2014-01-24 |
2022-07-20 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
CN110464847B
(zh)
|
2014-01-31 |
2024-02-09 |
第一三共株式会社 |
抗her2抗体-药物偶联物
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US10183996B2
(en)
|
2014-02-28 |
2019-01-22 |
Allakos Inc. |
Methods and compositions for treating Siglec-8 associated diseases
|
CN111973740A
(zh)
|
2014-03-21 |
2020-11-24 |
泰华制药国际有限公司 |
针对降钙素基因相关肽的拮抗剂抗体及其使用方法
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
WO2015150900A2
(en)
|
2014-03-31 |
2015-10-08 |
Debiopharm International Sa |
Fgfr fusions
|
CA2941029C
(en)
|
2014-04-10 |
2021-02-16 |
Obi Pharma Inc. |
Antibodies, pharmaceutical compositions and uses thereof
|
KR102445502B1
(ko)
|
2014-04-10 |
2022-09-21 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
TWI717319B
(zh)
|
2014-05-27 |
2021-02-01 |
中央研究院 |
得自類桿菌屬之岩藻糖苷酶及其用途
|
CN106661099A
(zh)
|
2014-05-27 |
2017-05-10 |
中央研究院 |
抗her2醣抗体及其用途
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
CN106573971A
(zh)
|
2014-05-27 |
2017-04-19 |
中央研究院 |
抗cd20醣抗体及其用途
|
AU2015267044A1
(en)
|
2014-05-28 |
2016-12-15 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
US20170362304A1
(en)
|
2014-08-20 |
2017-12-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring viscosity of protein solution
|
US9879042B2
(en)
|
2014-09-08 |
2018-01-30 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
WO2016042412A1
(en)
|
2014-09-16 |
2016-03-24 |
Symphogen A/S |
Anti-met antibodies and compositions
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
JP6877350B2
(ja)
|
2014-11-05 |
2021-05-26 |
ジェネンテック, インコーポレイテッド |
抗fgfr2/3抗体及びその使用方法
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
RS59805B1
(sr)
|
2014-11-07 |
2020-02-28 |
Sesen Bio Inc |
Unapređena il-6 antitela
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
WO2016102588A1
(en)
*
|
2014-12-22 |
2016-06-30 |
Genmab A/S |
Method for the production of antibodies
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
EP3789766A1
(de)
|
2015-01-24 |
2021-03-10 |
Academia Sinica |
Neuartige glycankonjugate und verfahren zur verwendung davon
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
CN114702581A
(zh)
|
2015-01-30 |
2022-07-05 |
台湾地区“中央研究院” |
增进抗体功效的通用糖型组合物及方法
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US10457737B2
(en)
|
2015-02-09 |
2019-10-29 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
TWI805046B
(zh)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
JP7005483B2
(ja)
|
2015-04-06 |
2022-02-10 |
バイオベラティブ ユーエスエー インコーポレイテッド |
ヒト化抗C1s抗体及びその使用方法
|
TWI703157B
(zh)
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Cd3特異性抗體、治療性雙特異性抗體及其用途
|
EP3095465A1
(de)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
JP6846362B2
(ja)
|
2015-06-17 |
2021-03-24 |
アラコス インコーポレイテッド |
線維性疾患を処置するための方法および組成物
|
KR20180019113A
(ko)
|
2015-06-19 |
2018-02-23 |
싸이트알엑스 코포레이션 |
제어된 약물 방출을 위한 전달 시스템
|
BR112017027690A2
(pt)
|
2015-06-29 |
2018-10-09 |
Daiichi Sankyo Co Ltd |
método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
|
WO2017015619A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
WO2017023861A1
(en)
|
2015-08-03 |
2017-02-09 |
The Regents Of The University Of California |
Compositions and methods for modulating abhd2 activity
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
ES2911015T3
(es)
|
2015-08-31 |
2022-05-17 |
Helixmith Co Ltd |
Receptores quiméricos de antígeno anti-sialil Tn
|
MX2018002610A
(es)
|
2015-09-02 |
2018-09-27 |
Immutep Sas |
Anticuerpos anti-lag-3.
|
CA3002789A1
(en)
|
2015-09-04 |
2017-03-09 |
Primatope Therapeutics Inc. |
Humanized anti-cd40 antibodies and uses thereof
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
JP6959912B2
(ja)
|
2015-09-23 |
2021-11-05 |
ジェネンテック, インコーポレイテッド |
抗vegf抗体の最適化変異体
|
BR112018005777A2
(pt)
|
2015-09-24 |
2018-10-09 |
Daiichi Sankyo Company, Limited |
anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produzir um anticorpo de interesse ou um fragmento do mesmo composição farmacêutica, e, uso de pelo menos um anticorpo
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
CN109071648B
(zh)
|
2015-10-23 |
2022-07-19 |
辉瑞有限公司 |
抗il-2抗体及其组合物和用途
|
WO2017075212A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use thereof
|
EP3378487B1
(de)
|
2015-11-18 |
2022-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Kombinationstherapie mit t-zell-neuausrichtendem antigenbindendem molekül gegen zelle mit immunsuppressiver funktion
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
MX2018008063A
(es)
|
2015-12-30 |
2018-11-29 |
Genentech Inc |
Uso de derivados de triptofano para formulaciones de proteina.
|
EP3397287A1
(de)
|
2015-12-30 |
2018-11-07 |
Genentech, Inc. |
Formulierungen mit reduziertem abbau von polysorbat
|
US10472422B2
(en)
|
2016-01-08 |
2019-11-12 |
Abgenomics International Inc. |
Tetravalent anti-PSGL-1 antibodies and uses thereof
|
TWI657096B
(zh)
|
2016-01-21 |
2019-04-21 |
輝瑞股份有限公司 |
對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
EP3426693A4
(de)
|
2016-03-08 |
2019-11-13 |
Academia Sinica |
Verfahren zur modularen synthese von n-glykanen und anordnungen davon
|
KR20180116215A
(ko)
|
2016-03-14 |
2018-10-24 |
추가이 세이야쿠 가부시키가이샤 |
암의 치료에 이용하기 위한 세포상해 유도 치료제
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
CR20180529A
(es)
|
2016-04-04 |
2019-03-21 |
Bioverativ Usa Inc |
Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
|
TWI697333B
(zh)
|
2016-04-22 |
2020-07-01 |
台灣浩鼎生技股份有限公司 |
經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法
|
RS61828B1
(sr)
|
2016-06-08 |
2021-06-30 |
Abbvie Inc |
Anti-b7-h3 antitela i antitelske konjugacije lekova
|
US10562975B2
(en)
|
2016-06-15 |
2020-02-18 |
The Regents Of The University Of Michigan |
CD6 antibody for treatment of T-cell mediated diseases or disorders
|
AU2017302038B2
(en)
|
2016-07-27 |
2024-03-21 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
US11643456B2
(en)
|
2016-07-29 |
2023-05-09 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
WO2018050833A1
(en)
|
2016-09-15 |
2018-03-22 |
Ablynx Nv |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
US10751414B2
(en)
|
2016-09-19 |
2020-08-25 |
Celgene Corporation |
Methods of treating psoriasis using PD-1 binding antibodies
|
SG10201912173RA
(en)
|
2016-10-07 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
TW202246327A
(zh)
|
2016-10-12 |
2022-12-01 |
美商生物維瑞提夫美國公司 |
抗C1s抗體及其使用方法
|
CN110267982B
(zh)
|
2016-10-19 |
2024-02-23 |
斯克利普斯研究所 |
具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
|
EP3532496A1
(de)
|
2016-10-28 |
2019-09-04 |
Banyan Biomarkers, Inc. |
Antikörper gegen ubiquitin c-terminale hydrolase l1 (uch-l1) und gliales fibrilläres saures protein (gfap) und verwandte verfahren
|
KR20190078648A
(ko)
|
2016-11-16 |
2019-07-04 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 방법
|
IL309526A
(en)
|
2016-11-17 |
2024-02-01 |
2Seventy Bio Inc |
TGFBeta signal converter
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
JP7274417B2
(ja)
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
4-1bb結合タンパク質及びその使用
|
US20200207846A1
(en)
|
2016-11-28 |
2020-07-02 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
SG10201912366YA
(en)
|
2016-12-22 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Anti-cd3 antibody and molecules comprising the antibody
|
JP7069476B2
(ja)
|
2017-01-06 |
2022-05-18 |
博奥信生物技▲術▼(南京)有限公司 |
ErbB2抗体およびその使用
|
TWI780104B
(zh)
|
2017-01-17 |
2022-10-11 |
日商第一三共股份有限公司 |
抗gpr20抗體及抗gpr20抗體-藥物結合物、以及其製造方法及用途
|
KR20240038146A
(ko)
|
2017-01-30 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
KR20190133160A
(ko)
|
2017-02-07 |
2019-12-02 |
다이이찌 산쿄 가부시키가이샤 |
항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
|
KR20190115042A
(ko)
|
2017-02-07 |
2019-10-10 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
RU2019127550A
(ru)
|
2017-03-03 |
2021-04-05 |
Ринат Ньюросайенс Корп. |
Анти-gitr антитела и способы их использования
|
AU2018236267A1
(en)
|
2017-03-14 |
2019-09-26 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases and disorders
|
US20200010528A1
(en)
|
2017-03-15 |
2020-01-09 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
WO2018174274A1
(ja)
|
2017-03-24 |
2018-09-27 |
全薬工業株式会社 |
抗IgM/B細胞表面抗原二重特異性抗体
|
EP3609915A1
(de)
|
2017-04-12 |
2020-02-19 |
Pfizer Inc |
Antikörper mit bedingter affinität und verfahren zur verwendung dafür
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
BR112019022912A2
(pt)
|
2017-05-05 |
2020-05-26 |
Allakos Inc. |
Métodos e composições para tratar doenças oculares alérgicas
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
WO2018220584A1
(en)
|
2017-06-02 |
2018-12-06 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
AU2018277310A1
(en)
|
2017-06-02 |
2019-12-12 |
Ablynx Nv |
Aggrecan binding immunoglobulins
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
US20210145828A1
(en)
|
2017-06-29 |
2021-05-20 |
Rutgers, The State University Of New Jersey |
Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
|
US20200115446A1
(en)
|
2017-06-30 |
2020-04-16 |
National University Corporation Hokkaido University |
Pediatric osteoporosis drug that does not cause growth disorder
|
SG11202000298VA
(en)
|
2017-07-14 |
2020-02-27 |
Pfizer |
Antibodies to madcam
|
TW202402805A
(zh)
|
2017-07-27 |
2024-01-16 |
日商第一三共股份有限公司 |
抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
|
JP6889328B2
(ja)
|
2017-07-31 |
2021-06-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
三次元構造に基づくヒト化方法
|
EP3444275A1
(de)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoklonaler antikörper anti-fgfr4
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
CN111164208B
(zh)
|
2017-09-29 |
2023-08-04 |
第一三共株式会社 |
抗体-吡咯并苯并二氮杂卓衍生物偶联物
|
WO2019070013A1
(ja)
|
2017-10-05 |
2019-04-11 |
第一三共株式会社 |
細胞傷害性t細胞枯渇用組成物
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
JP7235249B2
(ja)
|
2017-10-20 |
2023-03-08 |
学校法人兵庫医科大学 |
抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
CN111587123A
(zh)
|
2017-11-09 |
2020-08-25 |
品通治疗有限公司 |
用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
|
CA3083346A1
(en)
|
2017-11-28 |
2019-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand-binding activity
|
IL305268A
(en)
|
2017-11-30 |
2023-10-01 |
Centurion Biopharma Corp |
Maytansinoid-based drug delivery systems
|
EP4344747A2
(de)
|
2017-11-30 |
2024-04-03 |
LadRx Corporation |
Albuminbindende prodrugs von auristatin-e-derivaten
|
EP3732195A4
(de)
|
2017-12-28 |
2022-02-09 |
Chugai Seiyaku Kabushiki Kaisha |
Zytotoxizitätsinduzierendes therapeutikum
|
JP7458790B2
(ja)
|
2018-01-31 |
2024-04-01 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
WO2019152742A1
(en)
|
2018-02-01 |
2019-08-08 |
Pfizer Inc. |
Chimeric antigen receptors targeting cd70
|
TW201934580A
(zh)
|
2018-02-01 |
2019-09-01 |
美商輝瑞大藥廠 |
對cd70具特異性抗體及其用途
|
US11512127B2
(en)
|
2018-02-14 |
2022-11-29 |
Viela Bio, Inc. |
Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
|
US11859006B2
(en)
|
2018-03-05 |
2024-01-02 |
Saitama Medical University |
Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody
|
US20190269757A1
(en)
|
2018-03-05 |
2019-09-05 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
MX2020009526A
(es)
|
2018-03-12 |
2020-10-28 |
Zoetis Services Llc |
Anticuerpos anti-ngf y metodos de estos.
|
US20190345261A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
EP3797752A4
(de)
|
2018-05-21 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
In einem glasfläschchen verschlossene lyophilisierte formulierung
|
PE20210127A1
(es)
|
2018-05-23 |
2021-01-19 |
Pfizer |
Anticuerpos especificos para cd3 y sus usos
|
MX2020012607A
(es)
|
2018-05-23 |
2021-01-29 |
Pfizer |
Anticuerpos especificos para gucy2c y sus usos.
|
KR20210021522A
(ko)
|
2018-06-14 |
2021-02-26 |
블루버드 바이오, 인코포레이티드. |
Cd79a 키메라 항원 수용체
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
US20200025776A1
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
|
CA3106537A1
(en)
|
2018-08-08 |
2020-02-13 |
Genentech, Inc. |
Use of tryptophan derivatives and l-methionine for protein formulation
|
SI3883606T1
(sl)
|
2018-09-24 |
2023-10-30 |
Janssen Biotech, Inc. |
Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23
|
CA3114295A1
(en)
|
2018-09-28 |
2020-04-02 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
SG11202104993SA
(en)
|
2018-11-14 |
2021-06-29 |
Daiichi Sankyo Co Ltd |
Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
|
US11548941B2
(en)
|
2018-11-20 |
2023-01-10 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
|
US20220332838A1
(en)
|
2018-11-20 |
2022-10-20 |
Perseus Proteomics Inc. |
Agent for inhibiting iron uptake into cells
|
WO2020128864A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and effective method of treating lupus with anti-il12/il23 antibody
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
CN113508140A
(zh)
|
2019-02-28 |
2021-10-15 |
学校法人顺天堂 |
与切断型的突变型Calreticulin结合的抗体以及骨髄增殖性肿瘤的诊断、预防或治疗药
|
JP2022525145A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体組成物を生成するための製造方法
|
JP2022526493A
(ja)
|
2019-03-18 |
2022-05-25 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体を用いた小児被験者の乾癬の治療方法
|
EP3943108A4
(de)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
|
TW202102228A
(zh)
|
2019-03-25 |
2021-01-16 |
日商第一三共股份有限公司 |
抗體-吡咯并苯二氮呯衍生物結合物
|
KR20210141630A
(ko)
|
2019-03-25 |
2021-11-23 |
다이이찌 산쿄 가부시키가이샤 |
항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트
|
WO2020196712A1
(ja)
|
2019-03-27 |
2020-10-01 |
第一三共株式会社 |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲートとparp阻害剤の組み合わせ
|
CN113906042A
(zh)
|
2019-04-10 |
2022-01-07 |
中外制药株式会社 |
用于纯化fc区修饰抗体的方法
|
TW202110477A
(zh)
|
2019-04-17 |
2021-03-16 |
國立大學法人廣島大學 |
以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
|
EP3955923A1
(de)
|
2019-04-18 |
2022-02-23 |
The Regents Of The University Of Michigan |
Kombination mit checkpoint-inhibitoren zur behandlung von krebs
|
CA3137397A1
(en)
|
2019-04-19 |
2020-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
KR20220015445A
(ko)
|
2019-05-29 |
2022-02-08 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 접합체의 투약
|
JPWO2020246563A1
(de)
|
2019-06-05 |
2020-12-10 |
|
|
US20230340086A1
(en)
|
2019-06-19 |
2023-10-26 |
Christopher Roland Oelkrug |
Antibody-mediated neutralization of beta-lactamases
|
WO2021010326A1
(ja)
|
2019-07-12 |
2021-01-21 |
中外製薬株式会社 |
抗変異型fgfr3抗体およびその使用
|
EP4008350A4
(de)
|
2019-07-26 |
2023-06-14 |
Saitama Medical University |
Antikörper, der die extrazelluläre region von alk2/acvr1 erkennt
|
CN114364699B
(zh)
|
2019-09-04 |
2024-03-29 |
株式会社英仙蛋白质科学 |
红细胞增多症治疗药
|
CA3155172A1
(en)
|
2019-10-25 |
2021-04-29 |
Shinko HAYASHI |
Combination of anti-garp antibody and immunomodulator
|
JPWO2021107082A1
(de)
|
2019-11-27 |
2021-06-03 |
|
|
US20230135752A1
(en)
|
2020-03-27 |
2023-05-04 |
PhotoQ3 Inc. |
Medicament for killing tumor cells
|
JP7285495B2
(ja)
|
2020-03-30 |
2023-06-02 |
国立大学法人三重大学 |
二重特異的抗体
|
CN115379858A
(zh)
|
2020-04-06 |
2022-11-22 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
JPWO2021261546A1
(de)
|
2020-06-24 |
2021-12-30 |
|
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
AU2021315210A1
(en)
|
2020-07-28 |
2023-03-09 |
Chugai Seiyaku Kabushiki Kaisha |
Prefilled syringe formulation with needle with needle shield containing novel modified antibody
|
TW202220677A
(zh)
|
2020-07-31 |
2022-06-01 |
日商中外製藥股份有限公司 |
含有表現嵌合受體之細胞的醫藥組成物
|
CN116724236A
(zh)
|
2020-08-06 |
2023-09-08 |
美国比奥维拉迪维股份有限公司 |
患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
|
IL300764A
(en)
|
2020-08-27 |
2023-04-01 |
Juntendo Educational Found |
Antibody and composition of calr-cd3 mutant anti-clotting drugs
|
WO2022075439A1
(ja)
|
2020-10-08 |
2022-04-14 |
国立大学法人東海国立大学機構 |
抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
|
CN117425501A
(zh)
|
2021-01-13 |
2024-01-19 |
纪念斯隆凯特琳癌症中心 |
抗体-吡咯并苯二氮䓬衍生物缀合物
|
US20240115721A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
TW202302143A
(zh)
|
2021-03-12 |
2023-01-16 |
日商中外製藥股份有限公司 |
重症肌無力症之治療或預防用之醫藥組合物
|
CN117203232A
(zh)
|
2021-03-17 |
2023-12-08 |
瑞塞普托斯有限责任公司 |
用抗il-13抗体治疗特应性皮炎的方法
|
TW202304991A
(zh)
|
2021-03-29 |
2023-02-01 |
日商第一三共股份有限公司 |
穩定的多重特異性分子及其利用
|
TW202304508A
(zh)
|
2021-03-31 |
2023-02-01 |
美商百歐維拉提夫美國公司 |
減少冷凝集素疾病患者之手術相關溶血
|
TW202306989A
(zh)
|
2021-06-22 |
2023-02-16 |
瑞士商諾華公司 |
用於在治療化膿性汗腺炎中使用的雙特異性抗體
|
WO2023027164A1
(ja)
|
2021-08-26 |
2023-03-02 |
株式会社ペルセウスプロテオミクス |
Ros(活性酸素種)産生増強剤
|
WO2023042097A1
(en)
|
2021-09-15 |
2023-03-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
WO2023057871A1
(en)
|
2021-10-04 |
2023-04-13 |
Novartis Ag |
Surfactant stabilizers
|
TW202323810A
(zh)
|
2021-10-08 |
2023-06-16 |
日商中外製藥股份有限公司 |
預填充式注射器製劑的調製方法
|
WO2023090361A1
(ja)
|
2021-11-16 |
2023-05-25 |
国立大学法人鳥取大学 |
改変d領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
|
US20230357381A1
(en)
|
2022-04-26 |
2023-11-09 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
US20240010742A1
(en)
|
2022-06-10 |
2024-01-11 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2023245048A1
(en)
|
2022-06-15 |
2023-12-21 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
US20240025978A1
(en)
|
2022-06-24 |
2024-01-25 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|